Compare Adaptive Biotechnologies Corp (ADPT) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Microsoft — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B), while Microsoft trades at $500.1 (market cap $3.76T). The key difference: Microsoft is far larger — about 928.4× Adaptive Biotechnologies Corp's market cap, and Microsoft pays a 0.72% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MSFT | |
|---|---|---|
Market Cap | $4.05B | $3.76T |
Sector | Health | Technology |
52-Week High | $25.45 | $542.07 |
52-Week Low | $12.30 | $352.83 |
Enterprise Value | $4.12B | $3.74T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $506.06, up 1.21% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Analyst consensus remains overwhelmingly positive with 80.49% buy ratings and $552.73 price target, representing 9.2% upside potential. Recent news highlights Microsoft's AI leadership and cloud computing strength.
Microsoft presents a compelling investment case with strong financial performance and AI-driven growth prospects. Key opportunities include Azure cloud expansion and Copilot adoption, while risks involve increased capital expenditures and competitive pressures. The stock's current valuation at 28.19 P/E appears reasonable given growth trajectory, though investors should monitor execution on AI investments and macroeconomic conditions affecting tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
